Bavarian Nordic A/S (CPH: BAVA), a fully integrated biotechnology company, announced on Thursday a new phase 2 study, exploring the combination of its cancer vaccine, CV301, and Bristol-Myers Squibb's nivolumab (OPDIVO) in patients with metastatic colorectal cancer (mCRC).
Reportedly, CV301 is specifically designed to elicit T-cells against the tumour antigens CEA and MUC1, both of which are highly overexpressed in colorectal cancers.
This phase 2 randomised trial will enrol up to 74 patients with oligometastatic, microsatellite stable mCRC eligible for complete resection. Prior to surgical removal of their tumours, patients will be randomised to receive four cycles of either chemotherapy plus nivolumab or a combination of chemotherapy, nivolumab, and CV301.
After resection, patients will continue receiving respective treatments in each study arm. The trial, anticipated to begin enrolment before mid-year, will be led by Darren R. Carpizo, M.D, Ph.D, director of the Liver Cancer and Bile Duct Cancer Programme at Rutgers Cancer Institute in New Jersey.
CV301 is an immunotherapy candidate which is being developed under a CRADA with the National Cancer Institute (NCI). CV301 targets two tumour-associated antigens, CEA and MUC1, which are over-expressed in multiple solid tumours, including lung, bladder, colorectal and pancreatic cancers. CV301 is a poxvirus-based prime/boost vaccine that incorporates a modified version of vaccinia (MVA-BN, a proprietary technology of Bavarian Nordic) as a priming dose, followed by multiple fowlpox boosts, and encodes the TRICOM costimulatory molecules.
Bavarian Nordic is focused on the development of innovative and safe therapies against cancer and infectious diseases.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer